HVTN 094

Status:Completed
Phase:I
Principal Investigator(s):Susan Buchbinder
Objective:To test the safety and immune responses of a prime-boost regimen of two HIV vaccines— a DNA vaccine followed by a modified vaccinia Ankara (MVA) vaccine— in healthy, HIV-uninfected vaccinia-naive adults. *Data presented at the 2016 R4P conference in Chicago, Illinois showed that all vaccine regimens were well-tolerated and safe*
Prevention Option(s):HIV Vaccine
Study Design:
Arms and Assigned Interventions
Description
Mode of Delivery
ARMsExperimental
Official Code: NCT01571960
Related Publications:
Phase 1 safety and immunogenicity testing of DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like p
Poxvirus vector-based HIV vaccines.
Trial Sponsors: DAIDS, GeoVax Labs Inc.
Start Date
End Date
May 1, 2012
none
Enrollment:48
Age range: 18 Years ↔ 50 Years
Population:Cisgender Men, Cisgender Women